ELISA Kits:

COVID-19 IgM Monitoring of the immune response to COVID-19, in the early stage of the infection as an additional marker to PCR

COVID-19 IgAThe IgA assay is recommended, in addition to IgG and IgM, to:
(a) monitor the global immunological response of patients undergoing an acute infection and their follow-up to full recovery;
(b) specifically for testing patients with symptoms of the gastroenteric form of COVID-19 infection;

COVID-19 IgG Monitoring of the immune response to COVID-19. Recommended in particular for testing:

(a) infected individuals in follow-up serological testing and when recovered from the infection, negative for COVID-19 PCR, to assure they developed IgG antibodies to the virus, confirming a full recovery from the infection;

(b) health-care workers at risk of covid-19 infection to verify whether or not they developed IgG antibodies to the virus;

(c) individuals from normal population to study their acquired immune status against COVID-19 infection.

(d) human antibodies donors for a preliminary screening of hyper-immune sera as a possible candidate for an immunotherapeutic approach to the treatment of the disease;

COVID-19 IgG Confirmation Module-based Enzyme-Immuno-Assay for the Confirmation/typing of human samples screened as positive for IgG. The test is aimed to identify the specificity of antibodies to the major immunodominant COVID-19 antigens Nucleocapsid, Spike1 and  Spike2

COVID-19 Spike 1&2 IgG Semi-quantitative determination of IgG antibodies to COVID-19 Spikeantigens. Intended for testing:

a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing antiSpike IgG;

b) normal population for epidemiology studies on presence of potential “protective” IgG to COVID-19 Spike antigens;

c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies;

d) human donors, recovered from COVID-19 infection, positive for anti-Spike IgG for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;

e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike IgG antibodies;

COVID-19 IgG/IgM Confirmation and Typing Module-based Enzyme-Immuno-Assay for the Confirmation of samples positive for IgG and IgM antibodies to COVID 19 in first screening

COVID-19 RBD-ACE2 NeutralizzationEnzyme ImmunoAssay (ELISA) for the semi-quantitative determination of inhibition activity of RBD-ACE2 binding induced by antibodies to SARS-CoV-2 in human plasma and sera

COVID-19 ACE2-RBD Neutralization Variants (R&D)Enzyme ImmunoAssay (ELISA) for the determination of the neutralizing activity of antibodies to SARS-CoV-2 variants by ACE2-RBD binding inhibition

 

RealTime PCR Kits:

 COVID-19 RNA Vs 2 Lyophilised Format Multiplex Real –Time RT-PCR for detection of SARS-CoV-2

• Multiplex REAL TIME PCR Two targets regions for the Sars-CoV-2 genome, POL (RdRp gene) and NUC (N gene), in the same reaction tube
• Highly specific to SARS-CoV-2
• One-step lyophilized master mixes and reagents
• Endogenous (Human gene) Internal Control included as extraction/amplification reaction control
• Amplification Results ready in less than 90 minutes
• Validated on human respiratory tract specimens
• Easily adaptable on the most common Standard Thermal Cyclers. Validated on CFX96™ (Bio-Rad) and ABI7500/7300 (ABI).
• CE IVD reagent
• Shipping and Storage +2°C…+8°C. No special shipment or dry ice required

 

 

CLIA  Kits:  

For exclusive use in combination with our CLIA random access Instrument S.A.R.A.

DIA.CHEMILUX SARS.CoV-2 NCP IgM Monitoring of infected patients & the when testing the population & healthcare workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2

DIA.CHEMILUX SARS.CoV-2 NCP IgA Monitoring of infected patients & when testing the population and healthcare workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase.

DIA.CHEMILUX SARS.CoV-2 NCP IgG Monitoring of infected patients & when testing the population and healthcare workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2 molecular tests.

DIA.CHEMILUX SARS.CoV-2 Spike/RBD Ab

Intended for testing:

(a) Health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike antibodies.

(b) Normal population for epidemiology studies on presence of potetial “protective” Antibodies to SARS-CoV-2 Spike antigens.

(c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies.

(d) Human donors, recovered from COVID-19 infection, positive for anti-Spike I Antibodies for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease.

(e) Vaccinated individuals to assure a ralible positive immunization with development of anti Spike Antibodies.

 

Rapid Test kit

 COVID-19 SARS-CoV-2 Antigen Rapid Test for the determination of the SARS-CoV-2 Antigen in nasopharyngeal swab

APPLICATION: Customs Control – Public Screening – Asymptomatic – Under Quarantine

RELIABLE: Early detection of the COVID-19 virus antigen

RAPID: Results in 10-15 minutes

EASY: Easy to use, no extra apparatus necessary

SAMPLES: Nasopharyngeal swabs